Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03599752 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases
A Phase 2 study of Stage IV Colorectal Cancer AJCC v8 and Colorectal Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 6
- Study locations
NCT03599752 is a Phase 2 study of Stage IV Colorectal Cancer AJCC v8 and Colorectal Adenocarcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 107-participant average among 22 other Stage IV Colorectal Cancer AJCC v8 trials with a reported enrollment target (63% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT03599752, a Phase 2 study of Stage IV Colorectal Cancer AJCC v8 and Colorectal Adenocarcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase II trial studies how well chemotherapy and/or metastasectomy work in treating patients with colorectal adenocarcinoma that has spread to the lungs (metastases). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metastasectomy is a surgical procedure that removes tumors formed from cells that have spread from other places in the body. It is not yet known if chemotherapy and metastasectomy together works better in treating patients with metastatic colorectal adenocarcinoma with lung metastases.
Conditions Studied
Interventions
- DRUG Chemotherapy
- PROCEDURE Metastasectomy
Study Locations (6)
Texas
- Baylor Colllege of Medicine - Houston
- M D Anderson Cancer Center - Houston
Missouri
- Washington University School of Medicine - St Louis
Pennsylvania
- Thomas Jefferson University - Philadelphia
Ontario
- University Health Network Princess Margaret Cancer Center P2C - Toronto
Quebec
- University of Montreal - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-07-02 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03599752
The ClinicalTrials.gov registry entry for NCT03599752 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 107-participant average among 22 other Stage IV Colorectal Cancer AJCC v8 trials with a reported enrollment target (63% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Stage IV Colorectal Cancer AJCC v8 appearing as the primary indexed condition, and to 2 interventions - of which Chemotherapy is the first listed.
NCT03599752 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03599752 about?
NCT03599752 is a clinical study titled "Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases". This phase II trial studies how well chemotherapy and/or metastasectomy work in treating patients with colorectal adenocarcinoma that has spread to the lungs (metastases). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping th...
What is the current status of trial NCT03599752?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2018-07-02. Estimated completion is 2030-01-31.
What conditions does trial NCT03599752 study?
This clinical trial studies the following conditions: Stage IV Colorectal Cancer AJCC v8, Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8.
What interventions are being tested in trial NCT03599752?
The interventions under investigation include: Chemotherapy (DRUG), Metastasectomy (PROCEDURE).
Who is sponsoring clinical trial NCT03599752?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03599752 being conducted?
This trial has 6 study locations across Missouri, Pennsylvania, Texas, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Colorectal Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
ACTIVE NOT RECRUITING · Phase 2
-
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
RECRUITING · Phase 1
-
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.